New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
11:33 EDTICPTIntercept trial of Obeticholic Acid posted on ClinicalTrials.gov
A trial of Intercept's Obeticholic Acid was posted on ClinicalTrials.gov, with a stated main purpose to test the drug' effectiveness when used in patients with moderately severe alcoholic hepatitis. The researchers suspect that individuals with alcoholic hepatitis have certain abnormalities in how their body handles bile acids produced by the liver, the guidance said. Obeticholic acid has "been shown to affect bile acid abnormalities and thus it is possible that obeticholic acid may improve liver condition in individuals with alcoholic hepatitis," the website notes. Shares of Intercept are up 10%, or $27.38, to $305.00 in late morning trading. Reference Link
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
07:33 EDTICPTIntercept management to meet with Deutsche Bank
Subscribe for More Information
April 23, 2015
05:44 EDTICPTIntercept FLINT trial data shows OCA treatment increases fibrosis resolution
Subscribe for More Information
April 22, 2015
07:07 EDTICPTEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use